Pfizer presents 45 oncology abstracts at ESMO 2026

• Pfizer announced plans to present 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the ESMO Congress 2026.
• The presentations include 11 oral sessions covering established medicines and late-stage pipeline programs in breast, genitourinary, and lung cancers.
• Pfizer said the data will include results from studies involving PADCEV, TALZENNA, atirmociclib, sigvotatug vedotin, and tivunatamig.

Pfizer (NYSE:PFE) announced it will present data from 45 oncology research abstracts at the European Society for Medical Oncology Congress 2026, taking place October 23–27 in Madrid, Spain.

The presentations include 11 oral sessions covering Pfizer’s established cancer medicines and late-stage pipeline programs across breast cancer, genitourinary cancers, and lung cancer.

Pfizer said the presentations will include Phase 2 data from atirmociclib in hormone receptor-positive, HER2-negative advanced breast cancer, Phase 3 results from sigvotatug vedotin in previously treated non-small cell lung cancer, and updated data for tivunatamig in combination with chemotherapy.

Pfizer develops medicines across multiple healthcare areas, including oncology treatments such as PADCEV and TALZENNA, along with investigational therapies targeting different cancer pathways.

The company said additional ESMO presentations will include analyses from PADCEV plus pembrolizumab studies, TALZENNA plus XTANDI research in prostate cancer, and patient outcome data from multiple Phase 3 oncology trials.